SCHEMBL738288

SCHEMBL738288

CC(C)(CCn1c(=O)[nH]c2ccccc21)NC=O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
CYP1A2 P05177 1/20 0.52
KMT2A Q03164 1/20 0.52
LMNA P02545 3/20 0.50
HPGD P15428 2/20 0.50
HTT P42858 2/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
RAB9A P51151 1/20 0.47
POLB P06746 1/20 0.47
HTR7 P34969 6/20 0.44
P2RX7 Q99572 1/20 0.42
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL739301 0.82 MEN1 (0.63) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL3390372 0.81 MEN1 (0.51) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL738053 0.79 MEN1 (0.59) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL739035 0.79 MEN1 (0.59) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL13870499 0.79 MEN1 (0.49) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL27246567 0.76 MEN1 (0.55) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL1856433 0.74 LMNA (0.61) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL29695523 0.74 CYP1A2 (0.74) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL21729878 0.74 LMNA (0.64) MEN1CYP1A2KMT2ALMNAHPGD
SCHEMBL763168 0.74 CYP1A2 (0.74) MEN1CYP1A2KMT2ALMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138177-B2 Benzimidazolone derivatives as CB2 receptor ligands PFIZER INC. (US) 2012-03-20 US disclosed
EP-1861377-B1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS PFIZER (US) 2010-12-29 EP disclosed
US-20090298811-A1 BENZIMIDAZOLONE DERIVATIVES PFIZER INC 2009-12-03 US disclosed
US-20090181957-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS ANDO KAZUO 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298811-A1 BENZIMIDAZOLONE DERIVATIVES TRPV1, CNR1, CNR2 MEN1 2819/4885CYP1A2 1782/4885KMT2A 4384/4885
US-20090181957-A1 BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS TRPV1, CNR1, CNR2 MEN1 3613/4885CYP1A2 1751/4885KMT2A 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.